In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentActive18 and overNCINCI-2012-01969
CDR0000734205, RTOG 1122, U10CA180868, U10CA021661, NCT01609790

Trial Description

Summary

This partially randomized phase II trial studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with trebananib is more effective than bevacizumab alone in treating brain tumors.

Further Study Information

PRIMARY OBJECTIVES:

I. To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1). (closed to accrual 10/2/12) II. To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naïve patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).

SECONDARY OBJECTIVES:

I. To further assess the toxicity profile (Cohorts 1 and 2). II. To assess feasibility of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1 [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycles.

III. To determine the radiographic response rate (RR), median progression-free survival (PFS), and overall survival (OS) in bevacizumab-naïve patients (Cohort 2).

IV. To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).

V. To correlate outcome to treatment with tumor genotype, expression profile, and circulating angiogenesis biomarkers in tumor specimens (Cohort 2).

VI. To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).

VII. To determine the serum pharmacokinetics of AMG 386 in patients receiving bevacizumab (Cohort 1 and cross-over from placebo arm of Cohort 2).

OUTLINE: This is a safety study (cohort 1 [closed to accrual 10/2/12]) followed by a randomized study (cohort 2).

Cohort 1: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/2/12)

Cohort 2: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab and trebananib as in Cohort 1.

ARM II: Patients receive bevacizumab as in arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.

After completion of study treatment, patients are followed up at 30 days, every 2 months for 1 year, every 6 months for 1 year, and then annually thereafter.

Eligibility Criteria

Inclusion Criteria:

  • Histologically proven diagnosis of glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma); patients will be eligible if the original histology was a lower grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
  • The tumor must be supratentorial; patients with infratentorial disease, spinal cord disease, and/or leptomeningeal disease are excluded
  • Patients must have shown unequivocal evidence for tumor progression on the previous treatment regimen (prior to enrollment on this study) by magnetic resonance imaging (MRI) scan of the brain with and without contrast within 14 days prior to registration; the dose of steroids must be stable or decreasing for at least 5 days prior to the scan; patients with tumor progression who then undergo surgical resection prior to enrollment on study may be eligible as long as pathology confirms progressive or recurrent glioblastoma multiforme (GBM) (or variants); for patients who undergo surgical resection, registration on study may not occur any sooner than 28 days from surgery; an MRI scan of the brain with and without contrast is still required within 14 days prior to registration on study but is not required to demonstrate measurable disease or tumor progression after surgery
  • Patients unable to undergo MRI because of non-compatible devices can be enrolled, provided computed tomography (CT) scans are obtained and are of sufficient quality; patients without non-compatible devices may not have CT scans performed to meet this requirement
  • History/physical examination within 14 days prior to registration
  • Karnofsky performance scale >= 70
  • Patients who have received prior treatment with interstitial brachytherapy, stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of polifeprosan 20 with carmustine, must have confirmation of progressive disease within 14 days prior to registration based upon nuclear imaging, magnetic resonance (MR) spectroscopy, perfusion imaging, or histopathology
  • Leukocytes > 3,000/mm^3
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Hemoglobin >= 10.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dL is acceptable)
  • Platelets >= 100,000/mm^3
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal
  • Bilirubin =< 2.0 mg/dL
  • Creatinine within normal upper institutional limits or creatinine clearance > 60 mL/min/1.73 m^2 (per 24 hour urine collection or calculated according to the Cockcroft-Gault formula) for subjects with creatinine levels above the institutional normal
  • Patients with creatinine levels below normal institutional limits are eligible
  • Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
  • Urinary protein =< 30 mg/dL in urinalysis or =< 1+ on dipstick
  • Generally well-controlled blood pressure with systolic blood pressure =< 140 mm Hg AND diastolic blood pressure =< 90 mm Hg within 5 days prior to registration; the use of anti-hypertensive medications to control hypertension is permitted
  • Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test within 14 days prior to registration
  • Women of childbearing potential and male patients who are sexually active must practice adequate contraception during therapy and for 180 days (6 months) afterwards
  • Patient must provide study specific informed consent prior to study entry

Exclusion Criteria:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Prior systemic cytotoxic chemotherapy within (ie, =<) 28 days (42 days for nitrosoureas or mitomycin C) prior to registration, or patients who have not returned to baseline or =< Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v. 4) grade 2 from adverse events (excluding alopecia) due to agents administered more than 28 days prior to registration
  • Patients who received non-cytotoxic drug therapy must be off treatment for at least 14 days prior to registration; prior treatment with anti-vascular endothelial growth factor (VEGF) targeted agents; AMG 386 therapy; or other molecules that inhibit angiopoietins or TEK tyrosine kinase, endothelial (Tie2) receptor including, but not limited to, XL-820, XL-184 (cabozantinib-s-malate), and CVX-060/PF-4856884 is not allowed regardless of time frame
  • Patients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments
  • Treatment within 30 days prior to enrollment with strong immune modulators, including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, lenalidomide, and targeted immune modulators such as abatacept (CTLA-4-Ig), adalimumab, alefacept, anakinra, belatacept (LEA29Y), efalizumab, etanercept, infliximab, or rituximab
  • Prior radiotherapy within 90 days (3 months) prior to registration unless there is either: a) histopathologic confirmation of recurrent tumor; or b) new enhancement on MRI outside of the radiation treatment field
  • Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 28 days prior to registration or those patients who receive an non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain
  • Prior therapy with anti-VEGF targeted agents (e.g. bevacizumab, cediranib, vandetanib, aflibercept, sunitinib, sorafenib, etc.); prior therapy with thalidomide and lenalidomide is allowed as long as treatment has not occurred within 30 days prior to enrollment
  • More than 2 relapses
  • Therapeutic anticoagulation with warfarin < 7 days prior to registration; (therapeutic or prophylactic therapy with aspirin, a low-molecular weight heparin, or a Factor Xa inhibitor is acceptable)
  • Intratumoral hemorrhage or peritumoral hemorrhage, demonstrated by MRI or CT scan, CTCAE, v. 4 grade 2 or greater or evidence of significant hemorrhage (regardless of CTCAE, v. 4 grade) defined as > 1 cm diameter of blood (including postoperative hemorrhage)
  • Gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE, v. 4 grade 3 or greater within 30 days prior to study entry
  • Severe, active co-morbidity, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within 180 days (6 months) prior to registration
  • Transmural myocardial infarction within 180 days (6 months) prior to registration
  • History of stroke, cerebral vascular accident (CVA), or transient ischemic attack within 180 days (6 months) prior to registration
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
  • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
  • Known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
  • History of non-healing wounds or ulcers, or bone fractures within 90 days (3 months) prior to registration
  • History of venous or arterial thromboembolism within 12 months prior to registration
  • Prior allergic reaction to the study drugs involved in this study

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

Eudocia LeePrincipal Investigator

Trial Sites

U.S.A.
Alaska
  Anchorage
 Alaska Breast Care and Surgery LLC
 Matthew C Solhjem Ph: 503-215-6412
 Alaska Women's Cancer Care
 Matthew C Solhjem Ph: 503-215-6412
 Anchorage Oncology Centre
 Matthew C Solhjem Ph: 503-215-6412
 Katmai Oncology Group
 Matthew C Solhjem Ph: 503-215-6412
 Providence Cancer Center
 Matthew C Solhjem Ph: 503-215-6412
Arizona
  Scottsdale
 Arizona Oncology Services Foundation
 David G. Brachman Ph: 800-360-6371
  Tucson
 Arizona Oncology - Tucson
 Vivek S Kavadi Ph: 281-277-5200
California
  Los Angeles
 Kaiser Permanente Medical Center - Los Angeles
 Michael R Girvigian Ph: 626-564-3455
 USC/Norris Comprehensive Cancer Center and Hospital
 Rose K Lai Ph: 323-865-0451
 Rose K Lai Ph: 323-865-0451
  Orange
 Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
 Daniela A Bota Ph: 877-827-8839
  Email: ucstudy@uci.edu
 St. Joseph Hospital Regional Cancer Center - Orange
 Sam S Huang Ph: 714-541-6622
Colorado
  Fort Collins
 Poudre Valley Hospital
 Joshua H Petit Ph: 970-482-3328
 Poudre Valley Radiation Oncology
 Joshua H Petit Ph: 970-482-3328
Connecticut
  Hartford
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Samir Narayan Ph: 734-712-3456
  New Britain
 George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
 Neal B Goldberg Ph: 860-224-5660
  Norwich
 Eastern Connecticut Hematology and Oncology Associates
 Dennis E. Slater Ph: 860-886-8362
 William W. Backus Hospital
 Dennis E. Slater Ph: 860-886-8362
Florida
  Fort Lauderdale
 Broward General Medical Center Cancer Center
 Delia C Guaqueta Ph: 954-355-5346
Georgia
  Gainesville
 Northeast Georgia Medical Center
 Frank G. Lake Ph: 770-219-8800
  Email: cancerpatient.navigator@nghs.com
Idaho
  Boise
 Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
 Samir Narayan Ph: 734-712-3456
Illinois
  Aurora
 Rush-Copley Cancer Care Center
 Kendrith M. Rowland Ph: 800-446-5532
  Chicago
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Jeffrey J. Raizer Ph: 312-695-1301
  Email: cancer@northwestern.edu
 Rush Cancer Institute at Rush University Medical Center
 Robert D Aiken Ph: 312-942-5498
  Email: clinical_trials@rush.edu
 University of Chicago Cancer Research Center
 Martin K Nicholas Ph: 773-834-7424
  Danville
 Carle on Vermilion
 Kendrith M. Rowland Ph: 800-446-5532
  Effingham
 Carle Physician Group-Effingham
 Kendrith M. Rowland Ph: 800-446-5532
  Mattoon
 Carle Physician Group-Mattoon/Charleston
 Kendrith M. Rowland Ph: 800-446-5532
  Normal
 Community Cancer Center
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Pekin
 Cancer Treatment Center at Pekin Hospital
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Peoria
 Illinois CancerCare - Peoria
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 OSF St. Francis Medical Center
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Urbana
 Carle Cancer Center at Carle Foundation Hospital
 Kendrith M. Rowland Ph: 800-446-5532
 Kendrith M. Rowland Ph: 800-446-5532
  Warrenville
 Central Dupage Cancer Center
 Sean A Grimm Ph: 630-352-5300
  Email: cancer@northwestern.edu
  Yorkville
 Rush-Copley Healthcare Center
 Kendrith M. Rowland Ph: 800-446-5532
Kansas
  Overland Park
 Menorah Medical Center
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
 Saint Luke's Hospital - South
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Prairie Village
 CCOP - Kansas City
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
Maine
  Scarborough
 Maine Medical Center- Scarborough Campus
 Ian J Bristol Ph: 207-396-8090
  Email: wrighd@mmc.org
Michigan
  Ann Arbor
 CCOP - Michigan Cancer Research Consortium
 Samir Narayan Ph: 734-712-3456
 Saint Joseph Mercy Cancer Center
 Samir Narayan Ph: 734-712-3456
  Dearborn
 Oakwood Cancer Center at Oakwood Hospital and Medical Center
 Samir Narayan Ph: 734-712-3456
  Detroit
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Samir Narayan Ph: 734-712-3456
  Escanaba
 Green Bay Oncology, Limited - Escanaba
 James L Leenstra Ph: 920-433-8889
  Flint
 Genesys Hurley Cancer Institute
 Samir Narayan Ph: 734-712-3456
 Hurley Medical Center
 Samir Narayan Ph: 734-712-3456
  Iron Mountain
 Green Bay Oncology - Iron Mountain
 James L Leenstra Ph: 920-433-8889
  Kalamazoo
 Borgess Medical Center
 Raymond Sterling Lord Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Sterling Lord Ph: 269-373-7458
 West Michigan Cancer Center
 Raymond Sterling Lord Ph: 269-373-7458
  Lansing
 Sparrow Regional Cancer Center
 Samir Narayan Ph: 734-712-3456
  Livonia
 St. Mary Mercy Hospital
 Samir Narayan Ph: 734-712-3456
  Pontiac
 St. Joseph Mercy Oakland
 Samir Narayan Ph: 734-712-3456
  Port Huron
 Mercy Regional Cancer Center at Mercy Hospital
 Samir Narayan Ph: 734-712-3456
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Samir Narayan Ph: 734-712-3456
  Warren
 St. John Macomb Hospital
 Samir Narayan Ph: 734-712-3456
Minnesota
  Burnsville
 Fairview Ridges Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Coon Rapids
 Mercy and Unity Cancer Center at Mercy Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Edina
 Fairview Southdale Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Fridley
 Mercy and Unity Cancer Center at Unity Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Maplewood
 HealthEast Cancer Care at St. John's Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 Minnesota Oncology - Maplewood
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Minneapolis
 Hennepin County Medical Center - Minneapolis
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Robbinsdale
 Humphrey Cancer Center at North Memorial Outpatient Center
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Saint Louis Park
 CCOP - Metro-Minnesota
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 Park Nicollet Cancer Center
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Saint Paul
 Regions Hospital Cancer Care Center
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 United Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Waconia
 Ridgeview Medical Center
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Willmar
 Willmar Cancer Center at Rice Memorial Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
Mississippi
  Jackson
 University of Mississippi Cancer Clinic
 Mark D Anderson Ph: 601-815-6700
  Pascagoula
 Regional Cancer Center at Singing River Hospital
 James E. Clarkson Ph: 228-809-5292
Missouri
  Independence
 Independence Regional Health Center
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Kansas City
 Heartland Hematology Oncology Associates, Incorporated
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
 Research Medical Center
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
 Saint Luke's Hospital
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Lee's Summit
 Saint Luke's East - Lee's Summit
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Liberty
 Parvin Radiation Oncology
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Saint Joseph
 Heartland Regional Medical Center
 Rakesh Gaur Ph: 913-948-5588
  Email: aroland@kccop.org
  Saint Louis
 David C. Pratt Cancer Center at St. John's Mercy
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
  Springfield
 Hulston Cancer Center at Cox Medical Center South
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
 St. John's Regional Health Center
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
Nebraska
  Omaha
 Methodist Estabrook Cancer Center
 Tien-Shew W Huang Ph: 402-354-5144
New York
  Albany
 New York Oncology Hematology, PC - Albany
 Vivek S Kavadi Ph: 281-277-5200
 New York Oncology Hematology, PC at Albany Medical Center
 Susan A Weaver Ph: 518-489-3612ext1342
  Email: sharon.krause@usoncology.com
  Auburn
 Hematology Oncology Associates of Central New York-Auburn
 Dennis Jay Kotlove Ph: 315-472-7504
  Bronx
 Montefiore Medical Center
 Mary R Welch Ph: 718-904-2730
  Email: aecc@aecom.yu.edu
  East Syracuse
 CCOP - Hematology-Oncology Associates of Central New York
 Dennis Jay Kotlove Ph: 315-472-7504
  New York
 Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
 Andrew B Lassman Ph: 212-305-8615
 New York University Medical Center
 Joshua S Silverman Ph: 212-263-4434
  Email: prmc.coordinator@nyumc.org
  Rome
 Hematology-Oncology Associates of New York - Rome
 Dennis Jay Kotlove Ph: 315-472-7504
  Syracuse
 Hematology Oncology Associates of Central New York-Onondaga Hill
 Dennis Jay Kotlove Ph: 315-472-7504
North Carolina
  Asheville
 Mission Hospitals - Memorial Campus
 Christopher H Chay Ph: 828-213-4150
Ohio
  Akron
 Summa Center for Cancer Care at Akron City Hospital
 Charles A Kunos Ph: 330-375-6101
  Barberton
 Barberton Citizens Hospital
 Charles A Kunos Ph: 330-375-6101
  Belpre
 Strecker Cancer Center-Belpre
 Mark J Becker Ph: 614-566-4475
  Chillicothe
 Adena Regional Medical Center
 J. Philip Kuebler Ph: 614-566-3275
  Cincinnati
 University of Cincinnati
 Kevin P. Redmond Ph: 513-558-4553
  Email: uchealthnews@uc.edu
  Columbus
 CCOP - Columbus
 J. Philip Kuebler Ph: 614-566-3275
 Columbus Oncology Associates, Incorporated
 Mark J Becker Ph: 614-566-4475
 Doctors Hospital at Ohio Health
 J. Philip Kuebler Ph: 614-566-3275
 Grant Medical Center Cancer Care
 J. Philip Kuebler Ph: 614-566-3275
 Mount Carmel Health - West Hospital
 J. Philip Kuebler Ph: 614-566-3275
 Riverside Methodist Hospital Cancer Care
 J. Philip Kuebler Ph: 614-566-3275
 Zangmeister Center
 J. Philip Kuebler Ph: 614-566-3275
  Delaware
 Delaware Health Center
 Mark J Becker Ph: 614-566-4475
 Delaware Radiation Oncology
 Mark J Becker Ph: 614-566-4475
 Grady Memorial Hospital
 J. Philip Kuebler Ph: 614-566-3275
  Lancaster
 Fairfield Medical Center
 J. Philip Kuebler Ph: 800-446-5532
 Lancaster Radiation Oncology at Fairfield Medical Center
 Mark J Becker Ph: 614-566-4475
  Marietta
 Strecker Cancer Center at Marietta Memorial Hospital
 J. Philip Kuebler Ph: 614-566-3275
  Medina
 Summa Health Center at Lake Medina
 Charles A Kunos Ph: 330-375-6101
  Mount Vernon
 Knox Community Hospital
 J. Philip Kuebler Ph: 800-446-5532
  Newark
 Licking Memorial Cancer Care Program at Licking Memorial Hospital
 J. Philip Kuebler Ph: 614-566-3275
 Newark Radiation Oncology
 Mark J Becker Ph: 614-566-4475
  Portsmouth
 Southern Ohio Medical Center Cancer Center
 J. Philip Kuebler Ph: 614-566-3275
  Springfield
 Community Hospital of Springfield and Clark County
 J. Philip Kuebler Ph: 614-566-3275
  West Chester
 University Pointe
 Kevin P. Redmond Ph: 513-558-4553
  Email: uchealthnews@uc.edu
  Westerville
 Mount Carmel St. Ann's Cancer Center
 J. Philip Kuebler Ph: 614-566-3275
  Zanesville
 Genesis - Good Samaritan Hospital
 J. Philip Kuebler Ph: 614-566-3275
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Terence S. Herman Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
  Tulsa
 Cancer Care Associates-Yale
 Terence S. Herman Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Oregon
  Clackamas
 Clackamas Radiation Oncology Center
 Matthew C Solhjem Ph: 503-215-6412
  Eugene
 Willamette Valley Cancer Center - Eugene
 Vivek S Kavadi Ph: 281-277-5200
  Portland
 CCOP - Columbia River Oncology Program
 Matthew C Solhjem Ph: 503-215-6412
 Providence Cancer Center at Providence Portland Medical Center
 Matthew C Solhjem Ph: 503-215-6412
 Providence St. Vincent Medical Center
 Matthew C Solhjem Ph: 503-215-6412
Pennsylvania
  Beaver
 UPMC Cancer Center at Beaver Medical Center
 Frank Scott Lieberman Ph: 412-647-8073
  Bethlehem
 St. Luke's Cancer Network at St. Luke's Hospital
 Neil D Belman Ph: 610-954-3582
  Email: infolink@slhn.org
  Bryn Mawr
 Bryn Mawr Hospital
 Albert S DeNittis Ph: 866-225-5654
  Clairton
 UPMC Cancer Center at Jefferson Regional Medical Center
 Frank Scott Lieberman Ph: 412-647-8073
  Farrell
 UPMC Cancer Center at UPMC Horizon
 Frank Scott Lieberman Ph: 412-647-8073
  Gettysburg
 Adams Cancer Center
 Amit B. Shah Ph: 877-441-7957
  Greensburg
 UPMC Cancer Center - Arnold Palmer Pavilion
 Frank Scott Lieberman Ph: 412-647-8073
  Hanover
 Cherry Tree Cancer Center
 Amit B. Shah Ph: 877-441-7957
  Johnstown
 UPMC Cancer Center at the John P. Murtha Pavilion
 Frank Scott Lieberman Ph: 412-647-8073
  Lancaster
 Lancaster General Hospital
 Jeffery S Eshleman Ph: 717-544-5511
  McKeesport
 UPMC Cancer Center at UPMC McKeesport
 Frank Scott Lieberman Ph: 412-647-8073
  Natrona Heights
 UPMC Cancer Center - Natrona Heights
 Frank Scott Lieberman Ph: 412-647-8073
  New Castle
 Jameson Memorial Hospital - North Campus
 Frank Scott Lieberman Ph: 412-647-8073
  Paoli
 Cancer Center of Paoli Memorial Hospital
 Albert S DeNittis Ph: 866-225-5654
  Philadelphia
 Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
 Lyndon J Kim Ph: 215-955-6084
  Email: laura.lefko@umassmed.edu
  Pittsburgh
 St. Clair Memorial Hospital Cancer Center
 Frank Scott Lieberman Ph: 412-647-8073
 UPMC Cancer Center at UPMC Passavant
 Frank Scott Lieberman Ph: 412-647-8073
 UPMC Cancer Center at UPMC St. Margaret
 Frank Scott Lieberman Ph: 412-647-8073
  Seneca
 UPMC Cancer Center at UPMC Northwest
 Frank Scott Lieberman Ph: 412-647-8073
  Uniontown
 UPMC Cancer Center - Uniontown
 Frank Scott Lieberman Ph: 412-647-8073
  Washington
 Washington Hospital Cancer Center
 Frank Scott Lieberman Ph: 412-647-8073
  West Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Albert Yuen Ph: 610-988-9323
  Wynnewood
 CCOP - Main Line Health
 Albert S DeNittis Ph: 866-225-5654
 Lankenau Cancer Center at Lankenau Hospital
 Albert S DeNittis Ph: 866-225-5654
  York
 WellSpan Health
 Amit B. Shah Ph: 877-441-7957
South Carolina
  Anderson
 AnMed Cancer Center
 David S Martoccia Ph: 864-512-1000
  Email: rballew@anmedhealth.org
South Dakota
  Rapid City
 Rapid City Regional Hospital
 Michael J Swartz Ph: 605-716-3982
  Email: research@rcrh.org
Texas
  Austin
 Texas Oncology - Midtown Austin
 Vivek S Kavadi Ph: 281-277-5200
 Texas Oncology, PA at South Austin Cancer Center
 Vivek S Kavadi Ph: 281-277-5200
 Texas Oncology, PA at Texas Oncology Cancer Center - Central
 Vivek S Kavadi Ph: 281-277-5200
  Dallas
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 Edward Pan Ph: 214-648-7097
  Email: canceranswers@moffitt.org
 Texas Oncology, PA at Charles A. Sammons Cancer Center
 Vivek S Kavadi Ph: 281-277-5200
  Fort Worth
 Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital
 Vivek S Kavadi Ph: 281-277-5200
  Grapevine
 Texas Oncology-Grapevine
 Vivek S Kavadi Ph: 281-277-5200
  Longview
 Longview Cancer Center
 Bernard W Taylor Ph: 903-757-2122
  Round Rock
 Texas Oncology, PA - Seton Williamson
 Vivek S Kavadi Ph: 281-277-5200
 Texas Oncology, PA at Texas Cancer Center Round Rock
 Vivek S Kavadi Ph: 281-277-5200
  Sugar Land
 Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land
 Vivek S Kavadi Ph: 281-277-5200
  Tyler
 Tyler Cancer Center
 Vivek S Kavadi Ph: 281-277-5200
Utah
  American Fork
 American Fork Hospital
 Paula K Rauschkolb Ph: 801-507-3950
  Cedar City
 Sandra L. Maxwell Cancer Center
 Paula K Rauschkolb Ph: 801-507-3950
  Logan
 Logan Regional Hospital
 Paula K Rauschkolb Ph: 801-507-3950
  Murray
 Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
 Paula K Rauschkolb Ph: 801-507-3950
  Ogden
 Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
 Paula K Rauschkolb Ph: 801-507-3950
  Provo
 Utah Valley Regional Medical Center - Provo
 Paula K Rauschkolb Ph: 801-507-3950
  Saint George
 Dixie Regional Medical Center - East Campus
 Paula K Rauschkolb Ph: 801-507-3950
  Salt Lake City
 LDS Hospital
 Paula K Rauschkolb Ph: 801-507-3950
 Utah Cancer Specialists at UCS Cancer Center
 Paula K Rauschkolb Ph: 801-507-3950
Washington
  Vancouver
 Northwest Cancer Specialists at Vancouver Cancer Center
 Matthew C Solhjem Ph: 503-215-6412
 Southwest Washington Medical Center Cancer Center
 Matthew C Solhjem Ph: 503-215-6412
Wisconsin
  Antigo
 Langlade Memorial Hospital
 Darryl R. Barton Ph: 877-405-6866
  Green Bay
 Green Bay Oncology, Limited at St. Mary's Hospital
 James L Leenstra Ph: 920-433-8889
 Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
 James L Leenstra Ph: 920-433-8889
 St. Mary's Hospital Medical Center - Green Bay
 James L Leenstra Ph: 920-433-8889
 St. Vincent Hospital Regional Cancer Center
 James L Leenstra Ph: 920-433-8889
  Madison
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 H. Ian Robins Ph: 877-405-6866
  Manitowoc
 Holy Family Memorial Medical Center Cancer Care Center
 James L Leenstra Ph: 920-433-8889
  Marinette
 Bay Area Cancer Care Center at Bay Area Medical Center
 James L Leenstra Ph: 920-433-8889
  Menomonee Falls
 Community Memorial Hospital Cancer Care Center
 Jennifer M Connelly Ph: 414-805-4380
  Milwaukee
 Froedtert Hospital and Medical College of Wisconsin
 Jennifer M Connelly Ph: 414-805-4380
  Mukwonago
 D.N. Greenwald Center
 Wingate F. Clapper Ph: 262-928-7632
  New Richmond
 Cancer Center of Western Wisconsin
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Oconomowoc
 Regional Cancer Center at Oconomowoc Memorial Hospital
 Wingate F. Clapper Ph: 262-928-7632
  Oconto Falls
 Green Bay Oncology, Limited - Oconto Falls
 James L Leenstra Ph: 920-433-8889
  Sturgeon Bay
 Door County Cancer Center at Door County Memorial Hospital
 James L Leenstra Ph: 920-433-8889
 Green Bay Oncology, Limited - Sturgeon Bay
 James L Leenstra Ph: 920-433-8889
  Waukesha
 Waukesha Memorial Hospital Regional Cancer Center
 Wingate F. Clapper Ph: 262-928-7632
  Wausau
 University of Wisconcin Cancer Center at Aspirus Wausau Hospital
 Darryl R. Barton Ph: 877-405-6866
Canada
Saskatchewan
  Regina
 Allan Blair Cancer Centre at Pasqua Hospital
 Rashmi Koul Ph: 866-561-1026
  Email: CIO_Web@cancercare.mb.ca

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01609790
ClinicalTrials.gov processed this data on July 22, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top